Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. — Stella

Home/Cesarean Delivery Affecting Newborn/

View on ClinicalTrials.gov

Recruiting

Back to Cesarean Delivery Affecting Newborn trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Inova Health System, Falls Church, Virginia

Key details

Phase

Early testing / Safety & dosing

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

Johns Hopkins University, Rutgers University

Enrollment target

~600 participants

Started

July 2018

Primary completion

April 2027

Age range

0 Days – 50 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.